Clinical trials: Disease Free Survival
Survival Outcomes of Patients With Pulmonary LCNEC
Overall Survival of Large Cell Neuroendocrine Lung Cancer Patients - a Retrospective Study
This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to the analysis. Patients were treated with radical, palliative or symptomatic intension between 2002-2018 in central and north-eastern…
- Trial name
- NCT03998332
- Volunteers
- 132 people
- Sponsor
- Jaroslaw B. Cwikla, MD, PhD, Professor UWM
Breast Cancer
A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib
The aim of this study was to assess the effectiveness, safety, and tolerability of ribociclib in Indian women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast…
- Trial name
- RESONATE (NCT07363434)
- Where
- United States
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Stage II Colorectal Cancer, Stage III Colorectal Cancer
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis.
- Trial name
- NCT05086614
- Testing
- Thymosin Alpha1
- Where
- China
- Volunteers
- 2,500 people
- Sponsor
- Fudan University
Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety
Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial
Gastric cancer is the one of the leading cause of cancer death in the worldwide. Gastric cancer originates from the most superficial mucosal epithelial cells of the stomach wall, which can occur in various parts of the stomach…
- Trial name
- NCT03531931
- Testing
- Apatinib/Capecitatine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Stage III Gastric Cancer
Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer
Gastric cancer patients with stage III will be randomized to immune nutrition support or control group at discharge after total gastrectomy.
- Trial name
- CRUCIAL (NCT05253716)
- Testing
- ONS
- Where
- China
- Volunteers
- 696 people
- Sponsor
- Jinling Hospital, China
Esophageal Adenocarcinoma, Esophageal Cancer
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who…
- Conditions
- Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
- Trial name
- NCT05480384
- Testing
- Nivolumab, Trastuzumab deruxtecan
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Colorectal Cancer
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer.
- Trial name
- NCT01442155
- Testing
- Capecitabine, Oxaliplatin
- Where
- 9 sites in Slovakia
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Wound; Head, Multiple, Wound; Head, Scalp
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
This study will evaluate the use of free autologous dermal fat grafting (also called free dermal fat autografting) to treat complex craniofacial wounds that have failed standard treatment and to understand how well these grafts…
- Conditions
- Wound; Head, Multiple, Wound; Head, Scalp, Wound; Head, Wound Infection
- Trial name
- FTFDT3 (NCT03872544)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dufresne, Craig, MD, PC
Hepatocellular Carcinoma, RFS
Postoperative Adjuvant Therapy of HCC Based on PD-1
For the treatment of hepatocellular carcinoma, liver resection is still one of the optimal options, but the recurrence rate is as high as 70% five years after the operation, and the prognosis of patients with high-risk recurrence…
- Trial name
- NCT05307926
- Testing
- PD-1 inhibitors, TACE
- Where
- China
- Volunteers
- 573 people
- Sponsor
- Chen Xiaoping
Rectal Cancer
Prognostic Factors Affecting Recurrence and Disease-Free Survival After Surgical Resection for Cancer Rectum
Tumor recurrence after curative surgical resection for rectal cancer is a serious complication that greatly affects the overall morbidity and the outcome.
- Trial name
- NCT06096493
- Testing
- curative surgery for cancer rectum
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- South Valley University
Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
The goal of this phase II randomized controlled clinical trial is to evaluate whether adding lubiprostone to standard postoperative maintenance therapy can delay disease progression and recurrence in adult patients with…
- Conditions
- Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer, Peritoneal Metastasis, Colorectal Cancer (CRC)
- Trial name
- NCT07405736
- Testing
- maintenance therapy plus lubiprostone, maintenance therapy
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Ovarian Cancer
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
This study aims to test the hypothesis that the artificial prolongation of the platinum-free interval with a non-platinum treatment will improve the effectiveness of overall therapy in patients with ovarian cancer progression…
- Trial name
- MITO-8 (NCT00657878)
- Testing
- stealth liposomal doxorubicin, carboplatin, paclitaxel
- Where
- 40 sites in Belgium, Germany and 1 more
- Volunteers
- 215 people
- Sponsor
- National Cancer Institute, Naples
Prostate Cancer
Working Out M0 Bipolar Androgen Therapy
The WOMBAT study will test if BAT can prolong the time it takes for nmCRPC prostate cancer to become detectable in other areas of the body (metastatic disease).
- Trial name
- WOMBAT (NCT06594926)
- Testing
- Testosterone Enanthate
- Where
- 12 sites in Australia
- Volunteers
- 69 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Esophageal Squamous Cell Carcinoma
Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma (ESCC) ,20 patients enrolled in Phase Ib PALACE-1(NCT03792347).The results…
- Trial name
- PALACE-2 (NCT04435197)
- Testing
- Pembrolizumab Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Ruijin Hospital
Malignant Breast Neoplasm
Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy
The reduction in the number of fractions in radiotherapy is especially attractive in several senses, and even more so considering breast cancer, which has a high incidence and generally favorable prognosis.
- Trial name
- HYPHEN (NCT05665920)
- Testing
- Ultra-hypofractionated whole breast radiotherapy, Standard Radiation
- Where
- Brazil
- Volunteers
- 36 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Solid Neoplasms, Non-Small Cell Lung Cancer
PET/CT-Based Intratumoral Heterogeneity and Multimodal Imaging for Tumor Diagnosis and Prognosis
Background \& Rationale: Intratumoral heterogeneity (ITH) is a recognized hallmark and critical driver of therapeutic resistance, rapid disease progression, and poor survival across solid malignancies, notably advanced…
- Trial name
- NCT07906158
- Testing
- This is an observational study with no intervention.
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Shengjing Hospital
Sarcoma
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Sarcoma patients are at high risk for their cancer to recur even when the sarcoma has been removed surgically or treated with radiation or chemotherapy.
- Trial name
- NCT01141491
- Testing
- Trivalent ganglioside vaccine, OPT-821
- Where
- 13 sites in United States
- Volunteers
- 136 people
- Sponsor
- MabVax Therapeutics, Inc.
Non-small Cell Lung Cancer
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents.
- Trial name
- IMMUNOLUNG (NCT07608835)
- Testing
- prospective collection of blood and tumor samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Non-small Cell Lung Cancer, Progression, Disease
Energy for Lymphocytes
CERTIM is a cohort created in July 2015 to set up a multidisciplinary follow-up of cancer patients treated with immune checkpoint inhibitors.
- Trial name
- ELY (NCT04879316)
- Testing
- Resting Energy Expenditure measurement
- Where
- France
- Volunteers
- 144 people
- Sponsor
- Hôpital Cochin
Cervical Cancer Stage IA1, Cervical Cancer Stage IB1
Research of Circulating Tumor Cells Released During Cervical Cancer Surgery
Cervical cancer is a rare pathology. Recent studies showed that the risk of recurrence is higher for patients treated by coelioscopy in comparison with laparotomy.
- Conditions
- Cervical Cancer Stage IA1, Cervical Cancer Stage IB1, Cervical Cancer Stage IA2, Cervical Cancer Stage IB2
- Trial name
- CTC-COL (NCT04770090)
- Testing
- Blood samples
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier